USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
DORMATARG, INC.
Address:
3117 CASTLEROCK RD
OKLAHOMA CITY, OK 73120-1817
Phone:
N/A
URL:
N/A
EIN:
101089428
DUNS:
808090497
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $678,520.00 3
SBIR Phase II $1,991,632.00 1

Award List:

Drugs Targeting Dormant Tumors as Anti-Metastatic Agents

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$122,450.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Most cancer deaths occur from metastatic tumors rather than from the primary tumor alone. Although many of the new drugs in the past decade are directed against tumors , changes in overall cancer survival have only been modest. Most cures of cancer are still… More

Preventing bladder cancer recurrence and metastasis

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$259,133.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Bladder cancer kills approximately 13,000 Americans per year. At least half of these deaths are preventable with no improvements in screening because they occur in people who were initially diagnosed with superficial bl adder cancer. The problem is that bladder… More

Drugs Targeting Dormant Tumors as Anti-Metastatic Agents

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,991,632.00
Agency:
HHS
Principal Investigator:
Michael A. Ihnat – 405-271-2092
Abstract:
DESCRIPTION (provided by applicant): Most patients with solid tumors die of tumor recurrence at the same site or metastasis of the tumor to distal sites. An intermediate step in both recurrence and metastasis is a stage called tumor dormancy, where the cancer cells are suppressed by a normal… More

Identifying the drug target in dormant cancer cells

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$296,937.00
Agency:
HHS
Principal Investigator:
Paul Hauser – 405-271-2266
Abstract:
DESCRIPTION (provided by applicant): In spite of billions of dollars spent in the War on Cancer, cancer-specific mortality has changed little as a result, and the vast majority of cures are produced surgically, not from chemotherapy. The main problem is that even with early detection; most cancers… More